Developer docs
API playgroundTry for free, no card

Search company profiles

Photocure

Full company profile

uuid0028vql

Namestring
Photocure
Legal namestring
Photocure ASA
Websiteurl
photocure.com
Company typeenum
Public
Founded yearint
1993
Descriptiontext

Photocure ASA is a Norwegian commercial-stage diagnostics company specializing in uro-oncology precision diagnostics for bladder cancer. Founded in 1997 and headquartered in Oslo, Photocure markets Hexvix®/Cysview® (hexaminolevulinate HCl), a proprietary photosensitizing agent used during Blue Light Cystoscopy (BLC®) to make malignant cells fluoresce bright pink under blue light, improving tumor detection and complete resection compared to standard white light cystoscopy. Cysview is the tradename in the U.S. and Canada; Hexvix is the tradename elsewhere. The company also owns the largest bladder cancer patient registry in the world, with 3,100+ patients enrolled and a goal of 4,400+, used for real-world evidence and AI biomarker development.

The business model is primarily product sales of Hexvix/Cysview through two direct field sales forces—in North America (Princeton, NJ) and Europe (Düsseldorf, Germany)—with licensing and distribution partners in non-core markets including Asieris (China/Taiwan), Endotherapeutics (Australia/New Zealand), Genotests (Chile), IGL Medical (Israel), and Equity Pharmaceuticals (South Africa). The Cevira (APL-1702) asset, a photodynamic therapy for cervical precancer licensed globally to Asieris in 2019, generates milestone payments and royalties; Q1 2026 included NOK 125.6 million in Cevira milestone payments following China NMPA approval. In June 2026, Photocure acquired Vesica Health for approximately USD 30.5 million, adding AssureMDx, a urine-based molecular diagnostic test with FDA Breakthrough Device Designation, 96% sensitivity, and 99.7% NPV for early bladder cancer detection in hematuria patients.

Photocure serves urologists, hospitals, and clinics that perform cystoscopy procedures. FY2025 Hexvix/Cysview revenue was NOK 530 million (up 10% YoY in constant currencies), the company has delivered 11 consecutive quarters of positive commercial EBITDA, and the balance sheet held NOK 192.7 million in cash with no term debt at Q1 2026. The 413 active US accounts (+21% YoY) and 75+ Olympus Visera Elite III BLC systems deployed in Europe indicate ongoing commercial expansion, while AI partnerships with Artera, Intelligent Scopes, and Convergent Genomics—anchored on the BLC registry—position the company toward an AI-integrated bladder cancer diagnostics platform.

Short descriptiontext

Photocure ASA is a Norwegian commercial-stage diagnostics company that markets Hexvix/Cysview blue light cystoscopy products for bladder cancer detection, serving urologists, hospitals, and clinics across North America and Europe via direct sales and global partner distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bladder cancer diagnostics, blue light cystoscopy, uro-oncology pharmaceuticals, fluorescence cystoscopy imaging, urological cancer screening
Industry3 codes
PRIMARYHLAKAOAB
Urologic Oncology
SECONDARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code4 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Pharmaceutical Preparation Manufacturing325412
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
  • Pharmaceutical Preparations2834
Product category
Bladder Cancer Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Hexvix/Cysview Product Sales
TypeOthers
Description

Direct commercial sales of Hexvix (outside US/Canada) and Cysview (US/Canada) products for blue light cystoscopy procedures through established sales forces in North America and Europe.

prnewswire.com
2Milestone Payments
TypeLicensing Royalties
Description

Photocure receives milestone payments from Asieris for regulatory approvals of Cevira in various markets (China NMPA approval, EMA MAA acceptance). Q1 2026 included NOK 125.6 million in milestone payments for Cevira approvals.

prnewswire.com
3Cevira Licensing Royalties
TypeLicensing Royalties
Description

Photocure developed Cevira (APL-1702) and licensed global rights to Asieris in 2019. Photocure is eligible for milestone payments plus royalties on global sales of Cevira if commercially successful.

photocure.com
4Transfer Price and Royalties from Partners
TypeLicensing Royalties
Description

For Hexvix sold to Asieris for Chinese and Taiwanese markets, Photocure receives transfer price on manufactured product plus royalties on Asieris' sales.

photocure.com
5AssureMDx (post Vesica Health acquisition)
TypeOthers
Description

Urine-based molecular diagnostic test for early bladder cancer detection. Initial revenues expected in 2027 with positive EBITDA contribution by 2030.

photocure.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Hexvix
Description

Brand name for hexaminolevulinate HCl in all markets except U.S. and Canada; used during Blue Light Cystoscopy (BLC) to detect bladder cancer by making cancer cells glow bright pink.

photocure.com
+4 more records
Core offering1 text field

Photocure develops and commercializes Hexvix/Cysview (hexaminolevulinate HCl), a proprietary photosensitizing agent used with Blue Light Cystoscopy (BLC) to make bladder cancer cells glow bright pink, enabling improved tumor detection, more complete resection, and better disease management for urologists, hospitals, and clinics. The company also sells the Saphira BLC tower system in the US, distributes the AssureMDx urine-based molecular diagnostic test (acquired via Vesica Health in June 2026), and licenses Cevira (a photodynamic therapy for cervical precancerous lesions) to Asieris. Direct sales forces operate in North America and Europe; other geographies are served via distribution and licensing partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BLC significantly improved CIS detection (8.5% vs 3.4%) and increased BCG therapy use (31.0% vs 15.9%) over 3.5 years of follow-up
+4 more records
Product and service6 records
1Hexvix/Cysview (hexaminolevulinate HCl)
CategoryPharmaceutical diagnostic drug
Description

Proprietary photosensitizing agent that preferentially accumulates in bladder cancer cells, making them glow bright pink during Blue Light Cystoscopy (BLC). Sold as Cysview in the U.S./Canada and Hexvix in all other markets. Used by urologists, hospitals, and clinics for improved bladder tumor detection and complete resection.

2Blue Light Cystoscopy (BLC) Procedure
CategoryDiagnostic procedure
Description

Enhanced cystoscopy procedure pairing the Hexvix/Cysview agent with specialized blue light equipment to detect bladder cancer tumors that fluoresce bright pink, enabling more complete resection and better management decisions versus standard white light cystoscopy.

3Saphira Tower System
CategoryCapital equipment
Description

Proprietary blue light cystoscopy tower equipment system marketed to U.S. hospitals and urology practices to enable the BLC procedure with Cysview.

4AssureMDx
CategoryMolecular diagnostic test
Description

Multi-omic urine-based biomarker test integrating six epigenetic and somatic biomarkers for early bladder cancer detection in hematuria patients. Validated with 96% sensitivity, 99.7% NPV, and 0.96 AUC. Granted FDA Breakthrough Device Designation. To be offered through Vesica Health's CAP-accredited, CLIA-certified laboratory in Irvine, California.

5Cevira (APL-1702)
CategoryLicensed photodynamic therapy product
Description

Photodynamic drug-device combination product developed by Photocure for non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL/cervical precancerous lesions). Licensed to Asieris Meditech for global development and commercialization; Photocure receives milestone payments and royalties on global sales.

6ArteraAI Bladder Test
CategoryAI diagnostic biomarker test
Description

AI-powered digital pathology test under co-development that uses multimodal AI (MMAI) histopathology biomarkers combined with BLC registry data to provide prognostic and predictive insights for non-muscle invasive bladder cancer (NMIBC) management.

Scale indicator21 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Joint research initiative to evaluate and validate Artera's AI-powered ArteraAI Bladder Test using data from Photocure's U.S. BLC registry. The collaboration aims to develop multimodal AI histopathology biomarkers for NMIBC patients to improve disease grading, staging, and treatment decision-making.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

Photocure acquired Vesica Health for USD 30.5 million (net ~USD 28.5M after cash). Adds AssureMDx, a urine-based molecular test for early bladder cancer detection with 96% sensitivity and 99.7% NPV. USD 13.75M at close, USD 13.75M tied to Medicare milestones.

3Equity Pharmaceuticals PTY Limited
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-01
Description

Named Patient Program (NPP) agreement enabling bladder cancer patients in South Africa to receive BLC with Hexvix, entered in September 2024.

photocure.com
4IGL Medical
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-01
Description

Exclusive distribution agreement for Hexvix in Israel entered in June 2022.

photocure.com
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Exclusive distribution agreement for commercialization of Hexvix in Australia and New Zealand entered in Q1 2022.

6Genotests SpA
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-08-01
Description

Exclusive distributor for Hexvix in Chile appointed in August 2020.

photocure.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-07-01
Description

Photocure licensed global rights to Cevira (APL-1702) for treatment of HPV-induced cervical precancerous lesions to Asieris in July 2019. Additionally, Asieris obtained exclusive rights to register and commercialize Hexvix in China and Taiwan in January 2021. Photocure receives milestone payments and royalties on global sales of Cevira.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for flexible BLC expansion with co-developed 4K global Flex system targeted for global launch in 2027. Richard Wolf received approval for System blue BLC platform in China in April 2026.

9Intelligent Scopes Corporation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to develop AI software to support blue light cystoscopy for bladder cancer detection, with initial promising testing results and FDA approval as goal.

seekingalpha.com
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Leading global medtech company with CE mark for blue light-compatible systems in Europe, reinforcing growing recognition of BLC as important standard in bladder cancer management.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Trial comparing minimal residual disease outcomes between blue light and white light cystoscopy using Convergent Genomics' UroAmp biomarker at EAU 2026.

Strategic tierMinorTypeOthers
Description

Karl Storz submitted Citizen Petition for FDA reclassification of OAY equipment (diagnostic endoscopic light source systems) from Class III to Class II. FDA response indicated additional clinical evidence needed but maintained current classification.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Olympus is the dominant global manufacturer of flexible and rigid cystoscopes and the Visera Elite III BLC-compatible imaging system installed across Photocure's European footprint (75+ systems). As a broad medical/endoscopy incumbent, Olympus competes with Photocure-adjacent technologies while also serving as a critical distribution partner for BLC adoption.

TypeBroad incumbent
Description

Stryker is a large diversified medical device company with CE-marked blue light-compatible endoscopy systems in Europe, reinforcing BLC as standard in bladder cancer management. Comparable as a broad medtech incumbent participating in the BLC equipment ecosystem alongside Photocure's diagnostic drug business.

TypeDirect peer
Description

Karl Storz is a leading manufacturer of endoscopes and visualization systems used in urology, including cystoscopy equipment that Photocure's BLC technology integrates with. Filed the citizen petition for FDA OAY reclassification relevant to BLC equipment. Directly comparable as the upstream equipment partner for blue light cystoscopy procedures.

TypeEmerging player
Description

Veracyte is a molecular diagnostics company with a urologic oncology portfolio (including the Decipher Bladder test for bladder cancer recurrence risk). Comparable business model of proprietary molecular tests serving urology specialists, with a similar specialty oncology diagnostic commercial approach to Photocure's AssureMDx.

TypeEmerging player
Description

Nonagen Bioscience is an emerging cancer diagnostics company developing non-invasive bladder cancer detection technologies. Comparable as a niche emerging player with overlapping bladder cancer diagnostic focus, potentially competing with Photocure's AssureMDx in urine-based molecular testing.

TypeBroad incumbent
Description

Exact Sciences commercializes Cologuard, a non-invasive molecular screening test for colorectal cancer, and has expanded into multiple cancer screening/diagnostic indications. Comparable as a larger, established molecular diagnostics incumbent with a similar urine/stool-based biomarker test model targeting mass-market cancer screening markets.

TypeDirect peer
Description

Pacific Edge commercializes Cxbladder, a urine-based molecular diagnostic test for bladder cancer detection and recurrence monitoring. Directly comparable to Photocure's recently acquired AssureMDx in the non-invasive bladder cancer diagnostic category, serving the same hematuria evaluation and surveillance use cases.

TypeOthers
Description

Ferring Pharmaceuticals manufactures BCG (Bacillus Calmette-Guérin) immunotherapy, a primary treatment for non-muscle invasive bladder cancer that Photocure's BLC helps identify candidates for. Adjacent ecosystem participant - not a direct diagnostic competitor but a critical downstream therapy partner in bladder cancer management.

TypeOthers
Description

NeoGenomics operates a major cancer-focused diagnostics laboratory with urologic oncology testing capabilities. Comparable as a clinical laboratory services provider in oncology, sharing similar specimen handling and reimbursement dynamics with Photocure's Vesica Health/AssureMDx CLIA-certified lab operations.

TypeDirect peer
Description

Richard Wolf is a Germany-based endoscopy equipment manufacturer and a core Photocure partner co-developing a 4K flexible BLC system for 2027 global launch. Their System blue BLC platform received China approval in April 2026. Closely comparable as a specialty endoscopy peer and direct BLC ecosystem participant.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Photocure

Bladder Cancer Diagnosticsphotocure.com

Photocure ASA is a Norwegian commercial-stage diagnostics company that markets Hexvix/Cysview blue light cystoscopy products for bladder cancer detection, serving urologists, hospitals, and clinics across North America and Europe via direct sales and global partner distribution.

What Photocure does

Photocure ASA is a Norwegian commercial-stage diagnostics company specializing in uro-oncology precision diagnostics for bladder cancer. Founded in 1997 and headquartered in Oslo, Photocure markets Hexvix®/Cysview® (hexaminolevulinate HCl), a proprietary photosensitizing agent used during Blue Light Cystoscopy (BLC®) to make malignant cells fluoresce bright pink under blue light, improving tumor detection and complete resection compared to standard white light cystoscopy. Cysview is the tradename in the U.S. and Canada; Hexvix is the tradename elsewhere. The company also owns the largest bladder cancer patient registry in the world, with 3,100+ patients enrolled and a goal of 4,400+, used for real-world evidence and AI biomarker development.

The business model is primarily product sales of Hexvix/Cysview through two direct field sales forces—in North America (Princeton, NJ) and Europe (Düsseldorf, Germany)—with licensing and distribution partners in non-core markets including Asieris (China/Taiwan), Endotherapeutics (Australia/New Zealand), Genotests (Chile), IGL Medical (Israel), and Equity Pharmaceuticals (South Africa). The Cevira (APL-1702) asset, a photodynamic therapy for cervical precancer licensed globally to Asieris in 2019, generates milestone payments and royalties; Q1 2026 included NOK 125.6 million in Cevira milestone payments following China NMPA approval. In June 2026, Photocure acquired Vesica Health for approximately USD 30.5 million, adding AssureMDx, a urine-based molecular diagnostic test with FDA Breakthrough Device Designation, 96% sensitivity, and 99.7% NPV for early bladder cancer detection in hematuria patients.

Photocure serves urologists, hospitals, and clinics that perform cystoscopy procedures. FY2025 Hexvix/Cysview revenue was NOK 530 million (up 10% YoY in constant currencies), the company has delivered 11 consecutive quarters of positive commercial EBITDA, and the balance sheet held NOK 192.7 million in cash with no term debt at Q1 2026. The 413 active US accounts (+21% YoY) and 75+ Olympus Visera Elite III BLC systems deployed in Europe indicate ongoing commercial expansion, while AI partnerships with Artera, Intelligent Scopes, and Convergent Genomics—anchored on the BLC registry—position the company toward an AI-integrated bladder cancer diagnostics platform.

Photocure firmographics

Firmographics
Name
Photocure
Legal name
Photocure ASA
Website
https://photocure.com
Company type
Public
Founded year
1993
Operating status
Operating
Headcount range
101–250 employees
Short description
Photocure ASA is a Norwegian commercial-stage diagnostics company that markets Hexvix/Cysview blue light cystoscopy products for bladder cancer detection, serving urologists, hospitals, and clinics across North America and Europe via direct sales and global partner distribution.
Ownership category
akta.pro rank

Photocure industry classification

Industry
Product category
Bladder Cancer Diagnostics
NAICS
Surgical Appliance and Supplies Manufacturing (339113), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical Preparation Manufacturing (325412), Medical and Diagnostic Laboratories (62151)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAOAB
Urologic Oncology
SECONDARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Bladder cancer diagnostics
  • Blue light cystoscopy
  • Uro-oncology pharmaceuticals
  • Fluorescence cystoscopy imaging
  • Urological cancer screening

Where Photocure is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices4 records

Markets served

Photocure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain, Others

Revenue model

  1. Hexvix/Cysview Product Sales: Direct commercial sales of Hexvix (outside US/Canada) and Cysview (US/Canada) products for blue light cystoscopy procedures through established sales forces in North America and Europe.
  2. Milestone Payments: Photocure receives milestone payments from Asieris for regulatory approvals of Cevira in various markets (China NMPA approval, EMA MAA acceptance). Q1 2026 included NOK 125.6 million in milestone payments for Cevira approvals.
  3. Cevira Licensing Royalties: Photocure developed Cevira (APL-1702) and licensed global rights to Asieris in 2019. Photocure is eligible for milestone payments plus royalties on global sales of Cevira if commercially successful.
  4. Transfer Price and Royalties from Partners: For Hexvix sold to Asieris for Chinese and Taiwanese markets, Photocure receives transfer price on manufactured product plus royalties on Asieris' sales.
  5. AssureMDx (post Vesica Health acquisition): Urine-based molecular diagnostic test for early bladder cancer detection. Initial revenues expected in 2027 with positive EBITDA contribution by 2030.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels5 records

Photocure product offering

Product offering

Core offering

Photocure develops and commercializes Hexvix/Cysview (hexaminolevulinate HCl), a proprietary photosensitizing agent used with Blue Light Cystoscopy (BLC) to make bladder cancer cells glow bright pink, enabling improved tumor detection, more complete resection, and better disease management for urologists, hospitals, and clinics. The company also sells the Saphira BLC tower system in the US, distributes the AssureMDx urine-based molecular diagnostic test (acquired via Vesica Health in June 2026), and licenses Cevira (a photodynamic therapy for cervical precancerous lesions) to Asieris. Direct sales forces operate in North America and Europe; other geographies are served via distribution and licensing partners.

Differentiator

Problem solved

Functional benefit

Brands

  • Hexvix: Brand name for hexaminolevulinate HCl in all markets except U.S. and Canada; used during Blue Light Cystoscopy (BLC) to detect bladder cancer by making cancer cells glow bright pink.
  • Cysview
  • AssureMDx
  • BLC (Blue Light Cystoscopy)
  • Saphira

Products and services

  • Hexvix/Cysview (hexaminolevulinate HCl) Proprietary photosensitizing agent that preferentially accumulates in bladder cancer cells, making them glow bright pink during Blue Light Cystoscopy (BLC). Sold as Cysview in the U.S./Canada and Hexvix in all other markets. Used by urologists, hospitals, and clinics for improved bladder tumor detection and complete resection.
  • Blue Light Cystoscopy (BLC) Procedure Enhanced cystoscopy procedure pairing the Hexvix/Cysview agent with specialized blue light equipment to detect bladder cancer tumors that fluoresce bright pink, enabling more complete resection and better management decisions versus standard white light cystoscopy.
  • Saphira Tower System Proprietary blue light cystoscopy tower equipment system marketed to U.S. hospitals and urology practices to enable the BLC procedure with Cysview.
  • AssureMDx Multi-omic urine-based biomarker test integrating six epigenetic and somatic biomarkers for early bladder cancer detection in hematuria patients. Validated with 96% sensitivity, 99.7% NPV, and 0.96 AUC. Granted FDA Breakthrough Device Designation. To be offered through Vesica Health's CAP-accredited, CLIA-certified laboratory in Irvine, California.
  • Cevira (APL-1702) Photodynamic drug-device combination product developed by Photocure for non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL/cervical precancerous lesions). Licensed to Asieris Meditech for global development and commercialization; Photocure receives milestone payments and royalties on global sales.
  • ArteraAI Bladder Test AI-powered digital pathology test under co-development that uses multimodal AI (MMAI) histopathology biomarkers combined with BLC registry data to provide prognostic and predictive insights for non-muscle invasive bladder cancer (NMIBC) management.

Quantifiable outcome

  • BLC significantly improved CIS detection (8.5% vs 3.4%) and increased BCG therapy use (31.0% vs 15.9%) over 3.5 years of follow-up
  • +4 more outcomes

Companies that use Photocure

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Photocure technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability6 records

Feature4 records

Photocure partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, minor and secondary.

  • ArteracoreStrategic or Co-development Partner · 8 June 2026Joint research initiative to evaluate and validate Artera's AI-powered ArteraAI Bladder Test using data from Photocure's U.S. BLC registry. The collaboration aims to develop multimodal AI histopathology biomarkers for NMIBC patients to improve disease grading, staging, and treatment decision-making.
  • Vesica Health Inc.coreStrategic or Co-development Partner · 4 June 2026Photocure acquired Vesica Health for USD 30.5 million (net ~USD 28.5M after cash). Adds AssureMDx, a urine-based molecular test for early bladder cancer detection with 96% sensitivity and 99.7% NPV. USD 13.75M at close, USD 13.75M tied to Medicare milestones.
  • Equity Pharmaceuticals PTY LimitedminorChannel Partner/ Reseller/ Distributor · 1 September 2024Named Patient Program (NPP) agreement enabling bladder cancer patients in South Africa to receive BLC with Hexvix, entered in September 2024.
  • IGL MedicalsecondaryChannel Partner/ Reseller/ Distributor · 1 June 2022Exclusive distribution agreement for Hexvix in Israel entered in June 2022.
  • Endotherapeutics GroupsecondaryChannel Partner/ Reseller/ Distributor · 1 January 2022Exclusive distribution agreement for commercialization of Hexvix in Australia and New Zealand entered in Q1 2022.
  • Genotests SpAsecondaryChannel Partner/ Reseller/ Distributor · 1 August 2020Exclusive distributor for Hexvix in Chile appointed in August 2020.
  • Asieris Meditech Co., LtdcoreOEM/ Whitelabel/ Licensing Partner · 1 July 2019Photocure licensed global rights to Cevira (APL-1702) for treatment of HPV-induced cervical precancerous lesions to Asieris in July 2019. Additionally, Asieris obtained exclusive rights to register and commercialize Hexvix in China and Taiwan in January 2021. Photocure receives milestone payments and royalties on global sales of Cevira.
  • Richard WolfcoreStrategic or Co-development PartnerPartnership for flexible BLC expansion with co-developed 4K global Flex system targeted for global launch in 2027. Richard Wolf received approval for System blue BLC platform in China in April 2026.
  • Intelligent Scopes CorporationcoreStrategic or Co-development PartnerPartnership to develop AI software to support blue light cystoscopy for bladder cancer detection, with initial promising testing results and FDA approval as goal.
  • StrykersecondaryStrategic or Co-development PartnerLeading global medtech company with CE mark for blue light-compatible systems in Europe, reinforcing growing recognition of BLC as important standard in bladder cancer management.
  • Convergent GenomicsminorStrategic or Co-development PartnerTrial comparing minimal residual disease outcomes between blue light and white light cystoscopy using Convergent Genomics' UroAmp biomarker at EAU 2026.
  • Karl StorzminorOthersKarl Storz submitted Citizen Petition for FDA reclassification of OAY equipment (diagnostic endoscopic light source systems) from Class III to Class II. FDA response indicated additional clinical evidence needed but maintained current classification.

Scale indicators21 records

Recent moves7 records

Expansion highlights6 records

Photocure competitors and assessment

Company assessment

Broad incumbents

  • Olympus Corporation: Olympus is the dominant global manufacturer of flexible and rigid cystoscopes and the Visera Elite III BLC-compatible imaging system installed across Photocure's European footprint (75+ systems). As a broad medical/endoscopy incumbent, Olympus competes with Photocure-adjacent technologies while also serving as a critical distribution partner for BLC adoption.
  • Stryker: Stryker is a large diversified medical device company with CE-marked blue light-compatible endoscopy systems in Europe, reinforcing BLC as standard in bladder cancer management. Comparable as a broad medtech incumbent participating in the BLC equipment ecosystem alongside Photocure's diagnostic drug business.
  • Exact Sciences: Exact Sciences commercializes Cologuard, a non-invasive molecular screening test for colorectal cancer, and has expanded into multiple cancer screening/diagnostic indications. Comparable as a larger, established molecular diagnostics incumbent with a similar urine/stool-based biomarker test model targeting mass-market cancer screening markets.

Direct peers

  • Karl Storz: Karl Storz is a leading manufacturer of endoscopes and visualization systems used in urology, including cystoscopy equipment that Photocure's BLC technology integrates with. Filed the citizen petition for FDA OAY reclassification relevant to BLC equipment. Directly comparable as the upstream equipment partner for blue light cystoscopy procedures.
  • Pacific Edge Diagnostics: Pacific Edge commercializes Cxbladder, a urine-based molecular diagnostic test for bladder cancer detection and recurrence monitoring. Directly comparable to Photocure's recently acquired AssureMDx in the non-invasive bladder cancer diagnostic category, serving the same hematuria evaluation and surveillance use cases.
  • Richard Wolf: Richard Wolf is a Germany-based endoscopy equipment manufacturer and a core Photocure partner co-developing a 4K flexible BLC system for 2027 global launch. Their System blue BLC platform received China approval in April 2026. Closely comparable as a specialty endoscopy peer and direct BLC ecosystem participant.

Emerging players

  • Veracyte: Veracyte is a molecular diagnostics company with a urologic oncology portfolio (including the Decipher Bladder test for bladder cancer recurrence risk). Comparable business model of proprietary molecular tests serving urology specialists, with a similar specialty oncology diagnostic commercial approach to Photocure's AssureMDx.
  • Nonagen Bioscience: Nonagen Bioscience is an emerging cancer diagnostics company developing non-invasive bladder cancer detection technologies. Comparable as a niche emerging player with overlapping bladder cancer diagnostic focus, potentially competing with Photocure's AssureMDx in urine-based molecular testing.

Others

  • Ferring Pharmaceuticals: Ferring Pharmaceuticals manufactures BCG (Bacillus Calmette-Guérin) immunotherapy, a primary treatment for non-muscle invasive bladder cancer that Photocure's BLC helps identify candidates for. Adjacent ecosystem participant - not a direct diagnostic competitor but a critical downstream therapy partner in bladder cancer management.
  • NeoGenomics: NeoGenomics operates a major cancer-focused diagnostics laboratory with urologic oncology testing capabilities. Comparable as a clinical laboratory services provider in oncology, sharing similar specimen handling and reimbursement dynamics with Photocure's Vesica Health/AssureMDx CLIA-certified lab operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Photocure social profiles

Digital presence

Photocure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Photocure leadership team

Management profile

Number of profiles

Profiles7 records

Photocure subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Photocure funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Photocure M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Photocure

What does Photocure do?

Photocure develops and commercializes Hexvix/Cysview (hexaminolevulinate HCl), a proprietary photosensitizing agent used with Blue Light Cystoscopy (BLC) to make bladder cancer cells glow bright pink, enabling improved tumor detection, more complete resection, and better disease management for urologists, hospitals, and clinics. The company also sells the Saphira BLC tower system in the US, distributes the AssureMDx urine-based molecular diagnostic test (acquired via Vesica Health in June 2026), and licenses Cevira (a photodynamic therapy for cervical precancerous lesions) to Asieris. Direct sales forces operate in North America and Europe; other geographies are served via distribution and licensing partners.

Is Photocure a public or private company?

Photocure is a public company. It is classified as public and is currently operating.

When was Photocure founded?

Photocure was founded in 1993. It employs 101 to 250 people.

Where is Photocure based?

Photocure is headquartered in Oslo, Norway, in the Europe region.

How does Photocure make money?

Five revenue lines are on record. Hexvix/Cysview Product Sales are the primary driver. The others are milestone Payments, cevira Licensing Royalties, transfer Price and Royalties from Partners and assureMDx (post Vesica Health acquisition).

Who are Photocure's main competitors?

Broad incumbents on record are Olympus Corporation, Stryker and Exact Sciences. Direct peers are Karl Storz, Pacific Edge Diagnostics and Richard Wolf. Emerging players are Veracyte and Nonagen Bioscience. Others are Ferring Pharmaceuticals and NeoGenomics.

Does Photocure have an API?

No public API is recorded for Photocure.

What industry is Photocure in?

Photocure's product category is Bladder Cancer Diagnostics. Its primary akta.pro industry code is HLAKAOAB, Urologic Oncology, with a secondary code of HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienPhotocure partners with Clinigen on Named Patient Program broadening Access to Hexvix/Cysview (hexaminolevulinate HCl)Photocure ASA announced an agreement with Clinigen to supply Hexvix under a Named Patient Program in over 40 countries where the product is not approved or commercially available. The program, following a 2024 South Africa setup, allows physicians to prescribe Hexvix for blue light cystoscopy in bladder cancer patients. Clinigen will handle worldwide distribution from a UK warehouse.news.cision.comPhotocure partners with Clinigen on Named Patient Program broadening Access to Hexvix/Cysview (hexaminolevulinate HCl)Photocure ASA announced an agreement with Clinigen for global supply of Hexvix under a Named Patient Program starting in over 40 markets. The program enables physicians to prescribe the drug for bladder cancer patients in countries where it is not approved or commercially available. Clinigen will handle worldwide distribution from a UK central warehouse.AktienPhotocure Provides Update on AssureMDx and Anticipated Medicare Coverage TimelinePhotocure ASA updated its AssureMDx Medicare coverage timeline, noting CMS expects a final pricing determination before year-end 2026, effective January 1, 2027. Coverage remains on track for 2028, as the device was not included in the Nov. 6 LCD for urine-based biomarkers. The company cites strong clinical evidence, including a study showing 89% of microhematuria patients could avoid cystoscopy.Seeking AlphaPhotocure ASA (PHCUF) Q3 2026 Earnings Call TranscriptPhotocure ASA reported its Q3 2026 results on October 28, 2026, with CEO Daniel Schneider and new CFO Dennis Camporeale. The company highlighted its strategy of strengthening Hexvix and Cysview through expanded BLC installations, upgrades, and mobile adoption. It also aims to lead standard-setting for bladder cancer detection and surveillance.Investing.comEarnings call transcript: Photocure Q3 2026 revenue rises as shares fall 4.9%Photocure reported Q3 2026 revenue of NOK 140.9 million, up from NOK 135 million a year earlier, with Hexvix and Cysview product revenue rising 7% at constant currency. The stock fell 4.9% to $47.55, and the company raised its 2026 product revenue growth guidance to 10-12%.TradingViewPhotocure Q3 2026 Earnings Call Is LivePhotocure's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.PRESSBEEPhotocure ASA: Results for the third quarter of 2026 ...Middle EastPhotocure ASA reported Hexvix/Cysview revenues of NOK 134.2 million and Adjusted EBITDA of NOK 18.5 million for Q3 2026, down slightly from NOK 134.1 million and NOK 18.9 million in the prior quarter. The company also provided 2026 revenue guidance.PR NewswirePhotocure ASA: Results for the third quarter of 2026Photocure ASA reported Q3 2026 Hexvix/Cysview revenues of NOK 134.2 million and adjusted EBITDA of NOK 18.5 million. The company raised its 2026 product revenue growth guidance to 10-12% on constant currency, citing the FDA's proposed reclassification of BLC systems as a catalyst.